GSK, Theravance report Ph3 successes for COPD treatment

GlaxoSmithKline and Theravance are giving analysts a thumbs-up on their late-stage studies of Relovair, the next-gen COPD successor to Advair. Investigators say that the drug bested a placebo in the trials. A head-to-head trial pitting Relovair against Advair is underway. "Successful completion of these two studies is an important milestone in the development of Relovair for COPD," said Darrell Baker, head of Glaxo's respiratory medicine development program. "These data will be reviewed together with the larger 12-month exacerbation studies still under way, to develop a complete evaluation of Relovair in treating patients with COPD." Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.